Figure 2.
Effect of CDKN2A loss on overall survival of histologically classified lower grade (World Health Organization II-III) gliomas. (A–D) CDKN2A loss was associated with worse overall survival in lower grade gliomas not stratified by histology (A) and in astrocytomas (B), but not in oligodendrogliomas (C) or oligoastrocytomas (D).